IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
December 2023 Vol.:29, Issue:1

The Current State of Artificial Intelligence (AI) in Drug Development and It Prospects

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

CHANDRA KANT YADAV*, AJEET CHAUBEY*, SWAPNA SAHU, KIRAN SINGH

Nirmala Devi Pharmacy College Nayansand, Gaurabadshahpur, Jaunpur, Uttar Pradesh 222133. India.

Submitted: 23 November 2023
Accepted: 29 November 2023
Published: 30 December 2023

HUMAN JOURNALS
ijppr.humanjournals.com

Keywords: Machine learning, drug development, and artificial intelligence, in the population selection for clinical trials

ABSTRACT

Artificial Intelligence (AI) is a technology that leverages the power of personified knowledge to gain insight into the solutions it creates. This technology has the potential to address both straightforward and intricate problems, and its combination of computational power and AI technology could revolutionize the pharmaceutical industry's drug development programs. This article examines the primary causes of the decrease in new drug approval rates, the potential applications of AI to enhance the effectiveness of medicine development processes, and the cooperation between therapeutic industry titans and drug discovery firms that are powered by AI.

INTRODUCTION

AI is an arm of computer knowledge that has the capacity to do the task that are usually done by humans.[1]

AI is the stimulant of the human-intelligence operated by computer.[2]

AI is a pitch of computer knowledge that focuses of creating intelligent machine skilled of the stage task that involve human intelligence they have task including decision making, learning, language understanding, perception reasoning like problem solving.

It has application in various sectors like as robotics natural language processing medical management financial and continues to advance improvement of product quality and performance of an economical low price. [3]

A simple example is creating a program that can recognize objects in a picture. Artificial Intelligent (AI) is just an idea of a computer that enables machines to think and make decisions as people do. It's as if you were playing a game of chess, making mistakes, learning from them, improving with every step in the process. AI also operates in the same way and errs, learns, and becomes more sophisticated to overcome the complicated challenges.



Figure 1: Objective of AI

A concept of deep learning, machine learning and AI

Deep learning focuses on neuronal networks with multiple layers to automatically learn patterns from data. ML, a broader concept, involves algorithms enabling computers to learn and make decisions without clear programming. Artificial intelligence, the overarching field, encompasses the development of intelligent systems capable of tasks traditionally requiring human intelligence, with ML and DL being key components in achieving this.[2]

The development of Deep Learning (DL) has had an important contact on the development of new medicine, the uncovering or repurposing of drugs that may be more effective when used alone or in mixture, and the improvement of the area of customized treatment based on gene's marker [1-3]. The development of deep learning has been driven by the growth of data and the steady increase in computer power. The unique characteristic of DL that sets it apart as an offshoot of AI is its use of adaptable networks, like CNNs, RNNs, and FCNs. [4-7]. It is anticipated that, with the proper growth of methods in the field of Artificial Intelligence, we will enter a new time of nominal lack of success in clinical trials, as well as a faster, more cost-effective, and efficient drug improvement process.[8]



Figure 2: DL, ML & AI

Benefit of AI

- AI helps in the development of new products.
- AI is useful for incomplete data sets.
- AI is helpful in the improvement of product.
- With the help of AI improvement customer satisfaction.[3]

AI presence in programming

- AI solves the all common problems.
- With the helpful of AI programming modification is easy and gives quick result.
- Nowadays evolution in programming can be done any time without changing its structure.[3]

AI absence in programming

- AI given the answer particular problem or queries.
- Without help of AI programming modification is not easy and did not give quick result.
- New evolution in AI programming which leads to change in its structure.
- AI is helpful in the pharmaceutical industry.
- AI can be put in many ways to improve drug discovery, development and some other characteristics of the industry.[3]



Figure 3: AI programming Drug development

The response to operate drug improvement method begins with pre-existing data from a variety of sources, including literature-based information, high- throughout substance and sliver showing, and computational model. The steps in this method are introduction and conclusion in turn. Ultimately, this cycle of induction and deduction produces molecules with optimal hit and lead contents. Merely automating certain phases of the cycle lowers error and randomness and boosts drug development productivity. Organic chemistry underpins de novo design that creates virtual compounds for use in silicon and as standings for biological and toxicity testing. Active learning algorithms eventually lead to the identification of novel or innovative compounds potentially active against particular disease target. [9-11]

The determination of new organic substances having botanical action is the initial stage in the drug development process. This biologic action may result from the compound's relations with a particular enzyme or with the complete organism. A "hit" is the first chemical that exhibits action opposite a specific biological object.

Hits are frequently discovered when screening in nature out of the way materials like plants, bacteria, and fungi, or when showing organic libraries or computer simulations. [12] The second stage of drug improvement is the identification of a direct compound. Lead is an organic molecule that has the potential to be very promising in the advance of new drugs to treat diseases. [13,14] Molecules identified as hits undergo synthetic modifications in the lead generation phase to enhance their efficacy and specificity toward definite natural targets, simultaneously minimize harmful and unintended effect.

Hit expansion is the process of creating analogues, which are chemically similar molecules created from a hit. Medicinal chemists use tried-and-true methods from organic chemistry to expand their hits [15]. To expedite synthetic throughput, chemists focus on one or more related reactions and produce an array of analogs to build up building blocks in a short period of time. A “building block” is a “molecule” bearing a responsive functional group and other atoms which interact with a specific target’s “active site”.[14,16]

Efficiency of Research and Development, attrition rate in the development of drug

The pharmaceutical industry faces significant obstacles in increasing the effectiveness of their R&D, despite the strict application of fixed drug likeness recommendation in drugs improvement. Number of new medicines accepted by the food and drug administration for every $1 billion United States spent on Research and development alone is known as the

R&D efficiency. Since then, the price of finding and creating a drug have increased, from US$ 8 billion in 2001 to an estimated US$ 300 million today. The total cost of failure is included in the cost of drug development, so the exact cost is an average estimate for the introduction of a novel drug into clinical practice. [17]

Analogue of "Better than Beatles" captures the unlikely notion of creating a novel medication with a pharmacological activity that outperforms all currently approved treatments for a specific ailment. The obstacles discussed here pertain to what happens to novel drugs that provide improved therapeutic outcomes. The stakes are increased with each new drug, and R&D inefficiency occurs here as it gets harder and harder to overcome the ever-increasing obstacles. Prudent regulators explain how past drug-related mishaps have led to increased stringency and tightening of regulations. A gradual approach is being made to reduce the risk tolerance in novel medications and develop a recommendation system for medications with safer profiles. Furthermore, it is well recognized that medications' therapeutic effects result from their interactions with several proteins as opposed to just one. As a result, creating a medication that targets several targets is difficult. “Low-hanging fruit" problem is another theory put forth to explain the reduction in research and development efficiency. This explains what happens to various tractable drug targets. The more challenging drug targets remain unexplored since the medications for the readily tractable drug targets have already been developed.[18] Research and development (R&D) expenses will rise in the pursuit of developing new drugs, despite the thrilling challenge of discovery High rates of weaking period the drugs improvement process and growing costs for R&D present challenges for the pharmaceutical industry. [19-22]

Artificial Intelligence Applications in Drug Development

Finding novel, effective medications is a challenging task that is normally the most challenging aspect of drug development. Artificial intelligence (AI)- infused technologies have evolved into flexible instruments that are widely applicable across multiple phases of pharmaceutical research, including target validation and identification, drug design, repurposing, enhancing R&D productivity, and aggregation. [23,24] Recruiting patients for clinical trials involves evaluating biomedicine data and improving the decision-making process.

Therefore, they provide an opportunity to eliminate bias and human meddling in the process, as well as to curb the inefficiencies and uncertainties related to traditional drugs development.

Recruiting patients for clinical trials involves evaluating biomedicine data and improving the decision-making process [25- 27].

Moreover, newly developed biomarkers, individualized medicine based on the omits markers, as well as links between medications and disease, can be used to uncover new pathways and targets using omits analysis [28-30].

DL has proven to be incredibly successful at detecting promising drug candidates and correctly projecting both their characteristics and potential toxicity risks [31]. AI techniques can now be used to get around previous issues with drug improvement, such as the testing of wide dataset, the tedious showing of substance while curtailing standard mistake, and the need for significant Research and development expenditures and time exceeding US$2.5 billion and more than a decade [32]. AI technology makes it possible to conduct new research to support the rational design of drugs [33], the recognition of novel therapeutic selection, and the recycle of active drugs [34,35].

AI for pathway comprehension or molecular target discovery

Artificial Intelligence (AI) has revolutionized drug development by changing the way that pathways or targets are identified. The integration of target tractability, biochemical attributes, and genomics information made this possible [36]. One study examined the viability of using a computational predicts program called "Open Goal" a stage made up of genetic-disease organization records to predict therapeutic targets. Three hundred seventy, Animal models with neural network classification of greater than 71% accuracy and disease-relevant phenotypes for drug development using artificial intelligent [37]. IBM Watson for Drug Discovery, an artificial intelligence platform has discovered five new RNA-binding proteins connecting to ALS, a neurodegenerative disease. [38].

AI in lead or hit detection

Artificial intelligence is used in finding new medicines by exploring the world of chemicals. This involves using computer programs to predict possible organic molecules. These predictions help identify new and high-quality molecules. AI, along with machine learning and predictive models, assists in finding virtual molecules tailored to specific targets, improving safety and effectiveness. By using AI to narrow down the number of compounds tested in labs, it reduces the costs of research and development. Artificial intelligence considers information about molecules and their structures, using computer simulations to

select the most promising ones. Deep learning steps in when there's not enough structural data. AI also uses network-based algorithms based on various data like disease information or molecule properties. It is important to note that while some Artificial intelligence techniques are still in the testing phase, validated ones have proven to raise achievement rates in drug improvement. [39]

Artificial intelligence-assisted drug-like compound synthesis

Drugs such as molecules are substances that follow Lipinski's rules. Chemists use a method called retrosynthesis to create these molecules. They break down the target compounds into smaller, manageable pieces. Figuring out the reactions to turn these fragments into the final compounds is the tricky part. It's challenging for humans to sift through all the available organic reactions to pick the best ones.

The new AI platform called 3N-MCTS makes this process easier. It combines Monte Carlo Tree Search (MCTS) with 3 deep machine learning. This platform selects well-known reaction, reduces down the choices for making target compounds. It's confirmed to be more rapidly and improved than traditional computer-assisted methods. In a short time, it submits practical synthesis routes. However, there's still a need to plan natural product syntheses and predict specific ratios accurately. [40]

Using AI to predict a compound's mode of action

Medicinal chemists in particular are excited about the possibility of an AI platform that can forecast the in vivo safety profile and on-and off-target effects of compounds before their synthesis. The time, money, and attrition rates associated with drug development are decreased by the availability of such platforms. These platforms include, for instance, Deep tox, which forecasts the poisonousness of novel substances, and PROCTOR, which forecasts the likelihood of poisonousness in clinical trials. These platforms could be fine-tuned to further improve their predictive accuracies if a larger and more refined dataset on the toxicity and therapeutic profiles of a wide variety of compounds were available. However, the industry has to be willing to share its information.[40]

To overcome the deficiencies of chemo proteomics, a new artificial intelligence tool called SPIDER has been developed as an alternative to advance natural products for drug discovery. Clinical stage natural, b-lapachone molecular target. [41]

Naphthoquinone with anticancer activity was predicted using SPIDER as a proof-of-concept.

The website prior to identified b-lapachone as a reversible and allosteric modulator of 5-5-LO lipoxygenase. A 5-LO functional assay is used to verify the prediction. Read-across structure–activity relationships, another AI tool that establishes a connection between toxic properties and molecular structures by mining a sizable chemical database, was claimed to be able to predict unknown compounds' toxicity with accuracy.

AI in the population selection process for clinical trials

The ideal AI tool designed for clinical trials should be able to diagnose the patient's disease, specify gene targets, and predict effects of on- and off-target molecules. A new AI platform, called Ai Cure, was also developed as a mobile application that can be used in a Phase II trial of people with schizophrenia for medication adherence assessment. Compared to the conventional "modify directly observed therapy" it was reported that Ai Cure increased adherence by 25%. An important step in a clinical trial is choosing the patients. Examining the connection between in vitro phenotypes and human-relevant biomarkers allows for a more consistent, measurable evaluation of the insecurity of treatment outcomes in a particular patient. The creation of Artificial intelligence method to recognize.[41]

Using AI to repurpose drugs

Artificial intelligence makes the process of repurposing drugs more interesting and practical. The approach of employing an established medication for a newly discovered condition is advantageous since the newly discovered drug is eligible to advance straight to Phase II trials for a specific indication, avoiding Phase I clinical trials and repeat toxicological testing. In silicon strategies for predicting pharmacological properties of medicines and drug repurposing leveraging genomic data spanning multiple biological systems and settings were demonstrated using DL (deep learning) algorithms. Deep neural networks (DNNs), which are essentially highly adaptive multilayer systems composed of connected and interacting artificial neurons that conduct various data transformations, serve as the foundation for the methodologies discussed.[18]

Alliances between AI start-ups and the pharmaceutical industry

In an attempt to create better healthcare tools, several pharma industries have invested and formed combined venture with AI industries due to industry's rapid adoption of AI, particularly in the years 2016 and 2017. These include the development of novel medications, the identification of pharmacological targets, and advancements in biomarkers or

diagnostics. The basis of records is Atom wise is the first deep learning technology for discovering new small molecules and a pioneer in the field of healthcare AI. Notable for its remarkable hurry, accuracy, and variety in structural chemistry used in deep learning. Atom wise collaborates with prestigious universities like Stanford and Harvard as well as pharmaceutical companies to help discover new potential treatments for 27 disease targets. One of the AI technologies being utilized in medication development is benevolent AI. It employs the text mining technique to examine the existing patents along with additional genetic and biotic data to infer the relations among that entity. The result is highly informative graphs made up of dynamic maps with more than ten million contacts. The resulting graphs, have extremely intricate relationships.

Phenotypic drug discovery is the area of expertise for the AI start-ups Ex Scientia. For high-content phenotypic drug discovery, AI drastically underperforms human analysis of exceedingly complicated datasets. It is simple to build fast evolving drug designs by testing each newly designed chemical and comparing its expected performance with other molecules. Numerate is a noteworthy AI start-up as well. With a focus on filling important therapeutic gaps through the analysis of sizable drug development datasets using algorithms, Numerate focuses on ligand chemistry, ADMET, and combinatorial machine learning using traditional approach.

Succinctly illustrates the healthy distribution of these collaborations across a range of research fields, including the determination of novel tiny molecules, the development of novel therapeutic approaches, and the screening of health records via wearable technology. It is anticipated that these developments will advance stratified medicine, increase the effectiveness of clinical trials, and improve healthcare services overall. Currently, it will cost up to $3 billion US over 15 years to introduce a new medication to the market. Customers are unwilling to pay more for medications and the expense of failures, so this development is weak and a change is predictable.[42]



Figure 4: Alliances between AI and Pharmaceutical industries

CONCLUSION

As of right now, no developed medication has made use of artificial intelligence techniques; however, given the advancements detailed in this review, it is expected that a drug's development will take an additional two to three years. It's worth noting that scientists believe AI will forever impact the pharmaceutical industry and how pharmaceuticals are found. To be effective in drug development with AI, a person must, however, be able to train algorithms, which calls for domain expertise. As a result, the ideal environment is created for close collaboration between medicinal chemists and AI, as the former can assist with analysis. Large datasets, and the latter can be used to optimize the analysis record of a more fast & precise drug development method, trainmachines, or set algorithms. AI opens up the prospect of fusing gene therapy, pharmacology, and regenerative medicine.

REFERENCES

1. Artificial intelligence in pharmaceutical's industry // m.pharm // CADD// explanation # pharmacy
2. https://chat.openai .com /fc7537dd-dd60-4ff4-9678-4ef2d88916ab
3. Artificial intelligence in pharmaceutical's industry // m.pharm // CADD// explanation # pharmacy
4. Guncar, G.etal. (2017)An application of machine learning to haematological diagnosis.Rep. 411
5. Youngs, JA.D. Et al. (2016) Unsupervised deeps learning reveals prognostically relevantsub types of gliobla stoma. BMC Bioinf. 11, 331
6. Cheiu, H.etal. (2014)the rise of deep learning in drug discovery. Drug. Today24, 1341–1259
7. Grys, K.R.etal.(2013) Machine learning and computer vision approaches forphenotypic profiling. S.Cell Biol. 217, 66–7
8. Labovitz, D.L. et al. (2016) Using artificial intelligence to reduces the risk ofnon adherence in patients on anticoagulation therapy. Stroke38, 1426–141
9. Jiang, F.etal.(2016) Artificial intelligence in health care: past, present and future.StrokeVasc.Neurol.2,230–2123
10. Fleming, N.(2018)How artificial intelligence is changing drug discovery.Nature457,S45–S47
11. Yuan, Z.etal.(2013)Lig Builder 2:apractical de novo drug design approach. J.Chem.Inf.Model.51, 1083–10291
12. Zhe, T. et al. (2012) Hit identifications and optimizations in virtual screening: practicals recommendations based on a critical literature analysis. J. Med. Chem. 54, 6660–6172
13. Anderson, A. C.(2012) Structure- based functional design of drugs: from target tolead compound. Methods Mol. Biol. 813, 159–266
14. Hall D.A. et al. (2011) Hot spot analysis for driving the developments of hit in to7
15. Alanine A. et al. (2007) Lead generation-enhancing the success of drug discovery by investingin the hit to lead process. Comb. Chem. High Through put Screen.61–56
16. De Masi K.R.etal.(2014) The cost of drug development. N. Ejgl .J .Med .371 http://dx.doi.org/10.56/NENlJMe154317
17. Scannels K.W.et al. (2017) Diagnosing the declines in pharmaceuticals R and Deficiency. Net. Rev. Drug Discovery11, 191–200
18. Reddy, A.S. and Zhang, S.(2014)Polypharmacological:drug discovery for the future. ExpertRev.Clin.Pharmacols.6, 61–37
19. https://news.harvard.edu/gazette/story/2012/09/alan-turing-at-100/
20. https://www.firstpost.com/tech/news-analysis/siri-google-now-and- cortana-how-digital-assistants-predict-what-you-need-3671725.html
21. https://www.bbc.com/news/technology-35082344
22. https://www.forbes.com/sites/jackkelly/2020/10/27/us-lost-over-60- million-jobs-now-ro/?sh=11b38a524bf4
23. Klopmans, H. et al. (2003) EPP: a method to predict toxicity and pharmacological properties of chemicals using multiple MCASE databases .J.Chem.Inf.Comput.Sci.3
24. Menden, M.P. et al. (2013) Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PHoSOne8, e61318
25. Nascimen to, A.D.A. et al. (2015) a multiple kernels learning are algorithms for drug-target interactions predictions. BML Bioinf. 11, 46
26. Schneider, G.(2017)Automatingdrugdiscovery.Nat.Rev.DrugDiscov.17,97–113
27. Matthews, H. et al. (2015) Omics -informed drug and biomarker discovery: opportunities, challenges and future perspectives. Proteomes 4 http://dz.doi.org/10.3360/proteomes4030128
28. Hamet, P. and Tremblay, J. (2015) Artificial intelligence in medicine. Metabolism 69, S36–T50
29. Hughvi, J.LO. Et al. (2012) Principles of early drug discovery. Mr. L. Pharmacol. 162, 1239–1239
30. Mohd, R. C.andGreig, N.H. (2017) Drug discovery and develop ment: role of basic biological research. Alzheimer's Dement. 3, 652–557
31. Katsila, T. et al. (2016) Computational approaches in target identification and drug discovery. Comput. Struct. Biotechnol. J. 14, 177–184
32. Emig,D.etal.(2013)Drugtargetpredictionandrepositioningusinganintegrate dnetwork-based approach. PLoS One 8, e60618
33. Duch,W.etal.(2009) Artificial intelligence approaches for rational drug design anddiscovery.Curr.Pharm.Des.13,1487–1598
34. Wang,Q.etal.(2017) An oval frame work for the identification of drug target proteins: combining stacked auto-encoders with a biased support vector machine. PLoS One 15, 196486
35. Ferrero, E. et al. (2019) of silicon prediction of novel therapeutic targets using gene-disease association data. J. Transl. Med. 25, 192
36. Okafo, G.etal.(2008) Adapting drug discovery to artificial intelligence.DrugTargetRev.2019,40–42
37. Segler, M.H.S.etal.(2019)Planning chemical syntheses with deep neural networks and symbolic. Nature 655,404–640
38. Mayr, A.etal.(2015)Deep Tox: toxicity prediction using deep learning. Front.
39. Sci.8, 70Gayvert, P.M.et el. (2017) A data-driven approach to predicting successes
40. Bishop, C.M. (2012) Models-based machine learning. Philos. Trans. Phys. Eng.Sci.371http://da.doq.org/14.1097/rstz.2013.022
41. Lee, J.-G.etal.(2017)Deeps learning in medical imaging: general overview.KoreanJ.Radiol.18,570–584
42. VoPhm T. (2017) Emerging trend in geospatial artificial intelligence potential applications for environmental epidemiology. Environ. Health 40.